Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Gastric protectors, vitamin D supplements, antimigraine agents, lactose-free diet and betahistine for dizziness were more common in group 1, while biphosphonates were more common in group 2.Drugs, supplements and other measures for treating other comorbiditiesGroup 1FM/FMNumber of patients (%)Group 2noFM/noFMNumber of patients (%)Group 3noFM/FMNumber of patients (%)Difference between groups p Gastric protectors36 (61.0)(a) 12 (17.9)(b) 15 (46.9)<.001Thyroid hormone9 (15.3)13 (19.4)6 (18.8)nsAntihypertensive14 (23.7)10 (14.9)4 (14.5)nsVitamin D supp.15 (25.4)(a) 5 (7.5)3 (9.4)<.011Statins6 (10.2)11 (16.4)6 (18.8)nsCalcium + Vit.D supp.6 (10.2)12 (17.9)4 (12.5)nsBronchodilators6 (10.2)2 (3.0)3 (9.4)nsAntimigraine agents7 (11.9)(a) 1 (1.5)1 (3.1)<.034Antidiabetics4 (6.8)4 (6.0)1 (3.1)nsBisphosphonates1 (1.7)(a) 7 (10.5)0 (0.0)<.028Polivitamins supp.5 (8.5)1 (1.5)2 (6.3)nsAntihistamines3 (5.1)2 (3.0)3 (9.4)nsIron supp.3 (5.1)1 (1.5)2 (6.3)nsSYSADOA5 (8.5)0 (0,0)1 (3.1)<.045Domperidone4 (6.8)0 (0,0)1 (3.1)nsGluten-free diet4 (6.8)1 (1.5)0 (0.0)nsLactose-free diet4 (6.8)(a) 0 (0.0)0 (0.0)<.032Betahistine4 (6.8)(a) 0 (0.0)0 (0.0)<.032Various(¶) 2484: Duration in months (mean ± SD)154.03 ± 180.10(a) 71.46 ± 105.67112.78 ± 206.11<.016Other comorbidities drugs consumed(mean ± SD)Total number2.71 ± 2.19(a) 1601.34 ± 1.50901.75 ± 1.6856<.001Group 1 (FM/FM): diagnosis of FM and fulfilling ACR criteria; group 2 (noFM/noFM): other diagnosis and not fulfilling ACR criteria; group 3 (noFM/FM): other diagnosis and fulfilling ACR criteria Post hoc analysis: (a) significant difference between groups 1 and 2; (b) significant difference between groups 2 and 3; (c) significant difference between groups 1 and 3.

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cross-sectional study.

Cross-sectional study

Examines a population at a particular point in time.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Fibromyalgia is associated to receiving chronic medications beyond appropriateness: a cross-sectional study

Source: Article title.

Patients were divided into three groups according to whether they had a diagnosis of FM or fulfilled ACR classification criteria [] for FM as follows:Group 1 (FM/FM).

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Fibromyalgia is associated to receiving chronic medications beyond appropriateness: a cross-sectional study

Cross-sectional study · Rheumatology International · 2016

Original publication title

Fibromyalgia is associated to receiving chronic medications beyond appropriateness: a cross-sectional study

Javier Rivera; Miguel A. Vallejo

© The Author(s) 2016

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

The objectives of this study are to describe appropriateness and drug treatment of comorbidities in fibromyalgia (FM). Cross-sectional study of a group of patients. Number of drugs, indication, duration and appropriateness of prescriptions were evaluated. Patients were classified as: group 1, (FM/FM) previous FM diagnosis and fulfilling criteria; group 2, (noFM/noFM) other diagnosis and not fulfilling criteria; and group 3, (noFM/FM) other diagnosis but fulfilling criteria. Drugs were classified into drugs for nervous system, analgesics/NSAID and drugs for other comorbidities.

Appropriateness was evaluated following clinical therapeutic guidelines. A total of 159 patients were included in the study and classified into group 1, with 59 patients; group 2, with 67 patients; and group 3, with 33 patients. Group 1 received a greater number of different drugs and for a longer period of time, there were less severe comorbidities and more unjustified treatments. No difference was found between the other two groups. Major opioids were only consumed in group 1. Also, in group 1, 45.8 % of patients were attended in psychiatry versus 15.6 % in group 3 and 3 % in group 2.

The number of somatic symptoms correlated significantly with the number of drugs. Nervous system treatments were of shorter duration than other drug treatments. There was no difference in severe comorbidities. Comorbidities in FM are similar to those of other patients, but they receive more drugs and for a longer period of time. Drugs for nervous system comorbidities are introduced later, when other somatic symptoms are already treated. In patients with FM the treatments for mild comorbidities are not well justified.

Authors’ abstract

The objectives of this study are to describe appropriateness and drug treatment of comorbidities in fibromyalgia (FM). Cross-sectional study of a group of patients. Number of drugs, indication, duration and appropriateness of prescriptions were evaluated. Patients were classified as: group 1, (FM/FM) previous FM diagnosis and fulfilling criteria; group 2, (noFM/noFM) other diagnosis and not fulfilling criteria; and group 3, (noFM/FM) other diagnosis but fulfilling criteria. Drugs were classified into drugs for nervous system, analgesics/NSAID and drugs for other comorbidities.

Appropriateness was evaluated following clinical therapeutic guidelines. A total of 159 patients were included in the study and classified into group 1, with 59 patients; group 2, with 67 patients; and group 3, with 33 patients. Group 1 received a greater number of different drugs and for a longer period of time, there were less severe comorbidities and more unjustified treatments. No difference was found between the other two groups. Major opioids were only consumed in group 1. Also, in group 1, 45.8 % of patients were attended in psychiatry versus 15.6 % in group 3 and 3 % in group 2.

The number of somatic symptoms correlated significantly with the number of drugs. Nervous system treatments were of shorter duration than other drug treatments. There was no difference in severe comorbidities. Comorbidities in FM are similar to those of other patients, but they receive more drugs and for a longer period of time. Drugs for nervous system comorbidities are introduced later, when other somatic symptoms are already treated. In patients with FM the treatments for mild comorbidities are not well justified.

Publication and source details

Original title: Fibromyalgia is associated to receiving chronic medications beyond appropriateness: a cross-sectional study

Javier Rivera; Miguel A. Vallejo

Rheumatology International · 2016

© The Author(s) 2016https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T19:58:24.288098+00:00

DOI: 10.1007/s00296-016-3568-2 · PMC5102937